Ignite Creation Date:
2024-05-06 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 12:48 PM
Study NCT ID:
NCT03577925
Status:
UNKNOWN
Last Update Posted:
2018-07-05
First Post:
2018-06-24
Brief Title:
The Standard Management of HPV Infection
Sponsor:
Capital Medical University
Organization:
Capital Medical University
Study Overview
Official Title:
The Standard Mangagement of High-Risk HPV Infection During Follow-up Visits
Status:
UNKNOWN
Status Verified Date:
2018-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
High-risk human papillomavirus HR-HPV infection is a necessary condition in the occurence and development of cervical squamous intraepithelial lesion SIL and cervical cancer There are cases that high-grade SIL HSIL and stage IA1 cervical squamous cancer remain or reoccur or even become more severe after conization The infection situation of HR-HPV which plays an important role in the prognosis of cervical lesion should be consulted in the management and follw-up after conization It is worthwhile making further study in the specific practical significance of the HR-HPV in the prognosis of cervical lesion as well as the high-risk factors that influence the prognosis of HR-HPV
Detailed Description:
Main purposeTo work out the standard management of HPV infection by following up the HPV infection situation of the patients with high-grade SIL HSIL and stage IA1 cervical squamous cancer after conization
Research designFirst to do the retrospective analysis toward the patients who received conization between Jan 2009 to Aug 2016Secondto do the prospective analysis toward the patients who received conization between Spt 2016 to Aug 2018
Inclusive criteria of study populationThe patients who had finished HPV genotype testing before conizationwho had never received treatment other than conizationwho were histologically diagnosed as HSIL or IA1 cervical squamous cancerwho had not been diagnosed as any cervical diseases beforewho were under age 70who did not have any severe diseases that influence the follow-up
Follow-up methodsto do the follow-up to the target patients by 369121824 months after conization
Follow-up contentsthe HR-HPV genotype infection before conizationthe grade of lesionthe age when received conizationthe gravity and paritythe situation of the glands invovement
Research designFirst to do the retrospective analysis toward the patients who received conization between Jan 2009 to Aug 2016Secondto do the prospective analysis toward the patients who received conization between Spt 2016 to Aug 2018
Inclusive criteria of study populationThe patients who had finished HPV genotype testing before conizationwho had never received treatment other than conizationwho were histologically diagnosed as HSIL or IA1 cervical squamous cancerwho had not been diagnosed as any cervical diseases beforewho were under age 70who did not have any severe diseases that influence the follow-up
Follow-up methodsto do the follow-up to the target patients by 369121824 months after conization
Follow-up contentsthe HR-HPV genotype infection before conizationthe grade of lesionthe age when received conizationthe gravity and paritythe situation of the glands invovement
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None